Description: A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Target Patient Population: Advanced solid tumors with KRASG12C mutation
Study Design: Study Drug is given orally. Pembrolizumab supplied and given every 3 weeks IV.